Item 8.01. Other Events.
On January 30, 2020, Pulmatrix, Inc. (the "Company") issued a press release
announcing that the U.S. Food and Drug Administration has granted Fast Track
designation to Pulmazole, the Company's inhaled itraconazole antifungal being
developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients
with asthma. A copy of the press release is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release dated January 30, 2020
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses